Glaxo - Vir Biotech's COVID Treatment Approved In Japan - Roche Holding (OTC:RHHBF), Roche Holding (OTC:RHHVF), Regeneron Pharmaceuticals (NASDAQ:REGN), Roche Holding (OTC:RHHBY)

Japan's health ministry expert committee has approved GlaxoSmithKline Plc GSK - Vir Biotechnology Inc's VIR sotrovimab, a COVID-19 antibody therapy.
Related Link: GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients.
The approval covers patients with mild to moderate COVID-19 infection who do not require oxygen supplementation.
With the committee's backing, the health ministry is expected to grant the fast track OK for the single-dose intravenous treatment, Japan Times reported.
Regeneron Pharmaceuticals Inc REGN and Roche Holdings AG's RHHBY monoclonal antibody treatment, Ronapreve, has already been approved in Japan.
Sotrovimab was granted FDA Emergency Use Authorization in May for mild-to-moderate COVID-19 in those aged 12 years and above.
Related: Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug
The Committee for Human Medicinal Products of the European Medicines Agency has also issued a positive opinion for the treatment targeting adults and adolescents at risk of progressing to severe COVID-19.
Read Next: European Commission To Procure 220K Doses Of Glaxo-Vir Biotech's COVID-19 Antibody.
Price Action: VIR stock is up 2.67% at $44.99, GSK stock is up 0.29% at $38.50 during the market session on the last check Monday.

Glaxo - Vir Biotech's COVID Treatment Approved In Japan